Trastuzumab - BNF

Trastuzumab - BNF trastuzumab Trastuzumab prolongs survival in metastatic breast cancer patients whose tumors over express HER2 It is effective when given as a single agent or in trastuzumab trastuzumab emtansine continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients

trastuzumab Trastuzumab emtansine is a HER2-targeted, microtubule-stabilizing antibody-drug conjugate with about 3 chemotherapy molecules per antibody

trastuzumab Trastuzumab exposure for a relatively short period does not seem to substantially affect the pregnancy outcome In contrast, a more prolonged Intravenous trastuzumab is effective as a single-agent, and in combination with chemotherapy it significantly improves the median time to disease